-
公开(公告)号：US20180346484A1
公开(公告)日：2018-12-06
申请号：US15882008
申请日：2018-01-29
发明人： Irini Akritopoulou-Zanze , Wilfried Braje , Stevan W. Djuric , Noel S. Wilson , Sean C. Turner , Albert W. Kruger , Ana-Lucia Relo , Shashank Shekhar , Dennie S. Welch , Hongyu Zhao , Jorge Gandarilla , Alan F. Gasiecki , Huanqiu Li , Christina M. Thompson , Min Zhang
IPC分类号： C07D513/04 , C07D495/16 , C07D487/04 , C07D495/04 , C07D491/04 , C07D491/044
CPC分类号： C07D513/04 , C07D487/04 , C07D491/04 , C07D491/044 , C07D495/04 , C07D495/16
摘要： The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.
-
公开(公告)号：US20180127423A1
公开(公告)日：2018-05-10
申请号：US15643924
申请日：2017-07-07
发明人： Ying Wang , Jason T. Brewer , Irini Akritopoulou-Zanze , Stevan W. Djuric , Bhadra Shelat , Frauke Pohlki , Wilfried Braje , Ana-Lucia Relo
IPC分类号： C07D487/04 , C07D487/14 , C07D498/04 , C07D491/04 , C07D471/14 , C07D471/04
CPC分类号： C07D487/04 , C07D471/04 , C07D471/14 , C07D487/14 , C07D491/04 , C07D498/04 , Y02E60/321
摘要： The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.
-
3.发明授权公开(公告)号：US09650334B2
公开(公告)日：2017-05-16
申请号：US14215533
申请日：2014-03-17
发明人： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying X. Wang , Hongyu H. Zhao , Huan-Qiu Li , Jason T. Brewer , Irini Zanze , Justin Dietrich , Anil Vasudevan , Stevan W. Djuric , Yanbin Lao , Charles W. Hutchins
IPC分类号： A61K31/4025 , A61K31/44 , A61K31/4178 , C07D207/09 , C07D403/12 , C07D401/12 , C07D207/48 , C07D401/14 , C07D403/14 , C07D405/14 , C07D487/10 , C07D417/14 , C07D409/14 , C07D495/04 , C07D471/04 , C07D487/04
CPC分类号： C07D207/09 , A61K31/4025 , A61K31/44 , C07D207/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/10 , C07D495/04
摘要： The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
-
4.发明申请公开(公告)号：US20140275086A1
公开(公告)日：2014-09-18
申请号：US14215533
申请日：2014-03-17
发明人： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying X. Wang , Hongyu H. Zhao , Huan-Qiu Li , Jason T. Brewer , Irini Zanze , Justin Dietrich , Anil Vasudevan , Stevan W. Djuric , Yanbin Lao , Charles W. Hutchins
IPC分类号： C07D207/09 , C07D401/12 , C07D207/48 , C07D401/14 , C07D403/14 , C07D487/04 , C07D487/10 , C07D417/14 , C07D409/14 , C07D495/04 , C07D471/04 , C07D403/12 , C07D405/14
CPC分类号： C07D207/09 , A61K31/4025 , A61K31/44 , C07D207/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/10 , C07D495/04
摘要： The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
-
公开(公告)号：US09701679B2
公开(公告)日：2017-07-11
申请号：US14503198
申请日：2014-09-30
发明人： Ying Wang , Jason T. Brewer , Irini Akritopoulou-Zanze , Stevan W. Djuric , Bhadra Shelat , Frauke Pohlki , Wilfried Braje , Ana-Lucia Relo
IPC分类号： C07D487/04 , C07D471/04 , C07D471/14 , C07D491/04 , C07D498/04 , C07D487/14
CPC分类号： C07D487/04 , C07D471/04 , C07D471/14 , C07D487/14 , C07D491/04 , C07D498/04 , Y02E60/321
摘要： The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.
-
公开(公告)号：US09163007B2
公开(公告)日：2015-10-20
申请号：US14136359
申请日：2013-12-20
申请人： AbbVie Inc.
发明人： Irini Akritopoulou-Zanze , Brian D. Wakefield , Helmut Mack , Sean C. Turner , Alan F. Gasiecki , Vijaya J. Gracias , Kathy A. Sarris , Douglas M. Kalvin , Melissa J. Michmerhuizen , Qi Shuai , Jyoti R. Patel , Margaretha H. M. Bakker , Nicole Teusch , Eric F. Johnson , Peter J. Kovar , Stevan W. Djuric , Andrew J. Long , Anil Vasudevan , Dawn M. George , Lu Wang , Biqin Li , Nigel S. Moore , Adrian D. Hobson , Keith W. Woods , Julie M. Miyashiro , Steven L. Swann, Jr. , Thomas D. Penning
IPC分类号： C07D413/04 , C07D471/04 , C07D487/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/14 , C07D513/04
CPC分类号： C07D413/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04
摘要： The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
摘要翻译： 本发明涉及式（I）化合物或其药学上可接受的盐，其中A，R 1，R 2，R 3和m在说明书中定义。 本发明还涉及制备所述化合物的方法和含有所述化合物的组合物，其可用于抑制激酶例如糖原合成酶激酶3（GSK-3），Rho激酶（ROCK），Janus激酶（JAK），Cdc7，AKT ，PAK4，PLK，CK2，KDR，MK2，JNK1，极光，pim1和nek2。
-
公开(公告)号：US20140343066A1
公开(公告)日：2014-11-20
申请号：US14136359
申请日：2013-12-20
申请人： AbbVie Inc.
发明人： Irini Akritopoulou-Zanze , Brian D. Wakefield , Helmut Mack , Sean C. Turner , Alan F. Gasiecki , Vijaya J. Gracias , Kathy A. Sarris , Douglas M. Kalvin , Melissa J. Michmerhuizen , Qi Shuai , Jyoti R. Patel , Margaretha H.M. Bakker , Nicole Teusch , Eric F. Johnson , Peter J. Kovar , Stevan W. Djuric , Andrew J. Long , Anil Vasudevan , Dawn M. George , Lu Wang , Biqin Li , Nigel S. Moore , Adrian D. Hobson , Keith W. Woods , Julie M. Miyashiro , Steven L. Swann, Jr. , Thomas D. Penning
IPC分类号： C07D413/04 , C07D471/04 , C07D487/04 , C07D513/04
CPC分类号： C07D413/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04
摘要： The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
摘要翻译： 本发明涉及式（I）化合物或其药学上可接受的盐，其中A，R 1，R 2，R 3和m在说明书中定义。 本发明还涉及制备所述化合物的方法和含有所述化合物的组合物，其可用于抑制激酶例如糖原合成酶激酶3（GSK-3），Rho激酶（ROCK），Janus激酶（JAK），Cdc7，AKT ，PAK4，PLK，CK2，KDR，MK2，JNK1，极光，pim1和nek2。
-
公开(公告)号：US20130310368A1
公开(公告)日：2013-11-21
申请号：US13947995
申请日：2013-07-22
发明人： Ying Wang , Jason T. Brewer , Irini Akritopoulou-Zanze , Stevan W. Djuric , Bhadra Shelat , Frauke Pohlki , Wilfried Braje , Ana-Lucia Relo
IPC分类号： C07D487/04
CPC分类号： C07D487/04 , C07D471/04 , C07D471/14 , C07D487/14 , C07D491/04 , C07D498/04 , Y02E60/321
摘要： The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.
-
公开(公告)号：US09879033B2
公开(公告)日：2018-01-30
申请号：US14887171
申请日：2015-10-19
发明人： Irini Akritopoulou-Zanze , Wilfried Braje , Stevan W. Djuric , Noel S. Wilson , Sean C. Turner , Albert W. Kruger , Ana-Lucia Relo , Shashank Shekhar , Dennie S. Welch , Hongyu Zhao , Jorge Gandarilla , Alan F. Gasiecki , Huanqiu Li , Christina M. Thompson , Min Zhang
IPC分类号： A61K31/55 , C07D487/04 , C07D513/04 , C07D491/04 , C07D495/04 , C07D491/044 , C07D495/16
CPC分类号： C07D513/04 , C07D487/04 , C07D491/04 , C07D491/044 , C07D495/04 , C07D495/16
摘要： The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.
-
10.发明授权公开(公告)号：US09656955B2
公开(公告)日：2017-05-23
申请号：US14216222
申请日：2014-03-17
发明人： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying X. Wang , Hongyu H. Zhao , Huan-Qiu Li , Jason T. Brewer , Irini Zanze , Justin Dietrich , Anil Vasudevan , Stevan W. Djuric , Yanbin Lao , Charles W. Hutchins
IPC分类号： A61K31/4025 , A61K31/44 , A61K31/4178 , C07D207/09 , C07D403/12 , C07D401/12 , C07D207/48 , C07D401/14 , C07D403/14 , C07D405/14 , C07D487/10 , C07D417/14 , C07D409/14 , C07D495/04 , C07D471/04 , C07D487/04
CPC分类号： C07D207/48 , A61K31/4025 , A61K31/4178 , A61K31/44 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14
摘要： The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.177 秒)
